-
公开(公告)号：US11124489B2
公开(公告)日：2021-09-21
申请号：US16499050
申请日：2018-03-29
申请人： Jia Zhou , Zhiqing Liu , Na Ye , Fang Mei , Xiaodong Cheng
发明人： Jia Zhou , Zhiqing Liu , Na Ye , Fang Mei , Xiaodong Cheng
IPC分类号： C07D261/08 , C07D261/20 , A61P31/04 , A61P31/12
摘要： Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.
-
公开(公告)号：US20200255388A1
公开(公告)日：2020-08-13
申请号：US16499050
申请日：2018-03-29
申请人： Jia ZHOU , Zhiqing Liu , Na Ye , Fang Mei , Xiaodong Cheng
发明人： Jia ZHOU , Zhiqing Liu , Na Ye , Fang Mei , Xiaodong Cheng
IPC分类号： C07D261/08 , C07D261/20 , A61P31/04
摘要： Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.
-
公开(公告)号：US09737512B2
公开(公告)日：2017-08-22
申请号：US15066416
申请日：2016-03-10
申请人： Xiaodong Cheng , Fang Mei , Annemieke Kavelaars , Cobi J. Heijnen
发明人： Xiaodong Cheng , Fang Mei , Annemieke Kavelaars , Cobi J. Heijnen
IPC分类号： A61K31/42 , A61K31/422 , A61K31/41 , A61K31/275 , A61K31/33
CPC分类号： A61K31/422 , A61K31/275 , A61K31/33 , A61K31/42
摘要： Certain embodiments are directed to methods of treating pain, e.g., chronic or neuropathic pain, comprising administering an effective amount of an EPAC inhibitor.
-
公开(公告)号：US20160263088A1
公开(公告)日：2016-09-15
申请号：US15066416
申请日：2016-03-10
申请人： Xiaodong Cheng , Fang Mei , Annemieke Kavelaars , Cobi J. Heijnen
发明人： Xiaodong Cheng , Fang Mei , Annemieke Kavelaars , Cobi J. Heijnen
IPC分类号： A61K31/42
CPC分类号： A61K31/422 , A61K31/275 , A61K31/33 , A61K31/42
摘要： Certain embodiments are directed to methods of treating pain, e.g., chronic or neuropathic pain, comprising administering an effective amount of an EPAC inhibitor.
摘要翻译： 某些实施方案涉及治疗疼痛的方法，例如慢性或神经性疼痛，包括施用有效量的EPAC抑制剂。
-
5.发明申请METHODS OF TREATING RICKETTSIA USING EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS) INHIBITORS 审中-公开使用CAMP（EPACS）抑制剂直接激活的交换性蛋白质处理蜱虫的方法公开(公告)号：US20140348853A1
公开(公告)日：2014-11-27
申请号：US14455325
申请日：2014-08-08
申请人： Bin Gong , Xiaodong Cheng , David Walker , Fang Mei
发明人： Bin Gong , Xiaodong Cheng , David Walker , Fang Mei
CPC分类号： A61K31/42 , A61K45/06 , Y02A50/402
摘要： Embodiments of the invention are directed to compounds that inhibit an activity of EPAC proteins and methods of using the same.
摘要翻译： 本发明的实施方案涉及抑制EPAC蛋白活性的化合物及其使用方法。
-
6.发明申请Use of tumor susceptibilty gene 101 (TSG 101) as a prognostic and diagnostic marker 有权使用肿瘤易感基因101（TSG 101）作为预后和诊断标记公开(公告)号：US20070243547A1
公开(公告)日：2007-10-18
申请号：US11706109
申请日：2007-02-13
申请人： Xiaodong Cheng , Fang Mel , Travis Young , Jinsong Liu
发明人： Xiaodong Cheng , Fang Mel , Travis Young , Jinsong Liu
IPC分类号： A61K31/7088 , A61P35/00 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/178
摘要： The present invention discloses the link between oncogenic Ras and TSG101 and the negative effect of TSG101 on the expression of p21 in ovarian cancer. The present also discloses the use of TSG101 as a prognostic, diagnostic marker and a potential therapeutic target in cancer, especially ovarian cancer.
摘要翻译： 本发明公开了致癌Ras和TSG101之间的联系以及TSG101对卵巢癌p21表达的负面影响。 本发明还公开了TSG101作为癌症，特别是卵巢癌的预后，诊断标记和潜在治疗靶标的用途。
-
7.发明授权Compounds and compositions used to epigenetically transform cells and methods related thereto 有权用于表观遗传转化细胞的化合物和组合物及其相关方法公开(公告)号：US09458131B2
公开(公告)日：2016-10-04
申请号：US14356024
申请日：2012-11-08
申请人： Young-Sup Yoon , Xiaodong Cheng , Ji Woong Han , Antonello Mai
发明人： Young-Sup Yoon , Xiaodong Cheng , Ji Woong Han , Antonello Mai
IPC分类号： C07D239/72 , C07D211/08 , C07D211/56 , C07D401/12 , A61K31/517 , A61K45/06 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , C07D401/14
CPC分类号： C07D401/12 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61K45/06 , C07D401/14 , A61K2300/00
摘要： This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes.
摘要翻译： 本公开涉及表观遗传转化细胞的化合物，组合物和方法。 在某些实施方案中，本公开涉及产生表观遗传改变的细胞的方法，其包括将分离的细胞与本文所公开的组合物在形成表观遗传改变的细胞的条件下混合。 在某些实施方案中，本公开涉及将具有化学诱导多能性的细胞诱导细胞，例如成体体细胞或不是天然多能的细胞。 在某些实施方案中，本公开涉及本文公开的某些化合物，本文公开的化合物任选被一个或多个取代基，衍生物或其盐取代，用于这些目的。
-
8.发明授权Use of tumor susceptibilty gene 101 (TSG 101) as a prognostic and diagnostic marker 有权使用肿瘤易感基因101（TSG 101）作为预后和诊断标记公开(公告)号：US07897340B2
公开(公告)日：2011-03-01
申请号：US11706109
申请日：2007-02-13
申请人： Xiaodong Cheng , Fang Mel , Travis Young , Jinsong Liu
发明人： Xiaodong Cheng , Fang Mel , Travis Young , Jinsong Liu
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/178
摘要： The present invention discloses the link between oncogenic Ras and TSG101 and the negative effect of TSG101 on the expression of p21 in ovarian cancer. The present also discloses the use of TSG101 as a prognostic, diagnostic marker and a potential therapeutic target in cancer, especially ovarian cancer.
摘要翻译： 本发明公开了致癌Ras和TSG101之间的联系以及TSG101对卵巢癌p21表达的负面影响。 本发明还公开了TSG101作为癌症，特别是卵巢癌的预后，诊断标记和潜在治疗靶标的用途。
-
9.发明申请Novel druggable regions in set domain proteins, and methods of using the same 审中-公开定域蛋白中的新型药物区域及其使用方法公开(公告)号：US20070178523A1
公开(公告)日：2007-08-02
申请号：US10636508
申请日：2003-08-06
申请人： Xiaodong Cheng , Xing Zhang
发明人： Xiaodong Cheng , Xing Zhang
CPC分类号： C12Q1/48 , G01N33/5011 , G01N2333/91005 , G16B15/00 , Y02A90/26
摘要： The present invention relates to novel druggable regions discovered in histone H3 lysine methyltransferase DIM-5, which is a SET domain protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases in which the activity of SET domain proteins are implicated, for example, anti-cancer/anti-proliferative agents or anti-fungal agents.
摘要翻译： 本发明涉及在组蛋白H3赖氨酸甲基转移酶DIM-5（其是SET结构域蛋白）中发现的新的可药用区域。 本发明还涉及使用可药用区域筛选潜在的候选治疗剂用于涉及SET结构域蛋白的活性的疾病的方法，例如抗癌/抗增殖剂或抗真菌剂。
-
10.发明申请COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO 有权用于环境转化细胞的化合物和组合物及其相关方法公开(公告)号：US20140294764A1
公开(公告)日：2014-10-02
申请号：US14356024
申请日：2012-11-08
申请人： Young-Sup Yoon , Xiaodong Cheng , Ji Woong Han , Antonello Mai
发明人： Young-Sup Yoon , Xiaodong Cheng , Ji Woong Han , Antonello Mai
IPC分类号： C07D401/12 , A61K31/551 , A61K45/06 , A61K31/541 , A61K31/55 , C07D401/14 , A61K31/517 , A61K31/5377
CPC分类号： C07D401/12 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61K45/06 , C07D401/14 , A61K2300/00
摘要： This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes.
摘要翻译： 本公开涉及表观遗传转化细胞的化合物，组合物和方法。 在某些实施方案中，本公开涉及产生表观遗传改变的细胞的方法，其包括将分离的细胞与本文所公开的组合物在形成表观遗传改变的细胞的条件下混合。 在某些实施方案中，本公开涉及将具有化学诱导多能性的细胞诱导细胞，例如成体体细胞或不是天然多能的细胞。 在某些实施方案中，本公开涉及本文公开的某些化合物，本文公开的化合物任选被一个或多个取代基，衍生物或其盐取代，用于这些目的。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.026 秒)